The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Cancer incidence, patterns, and genotype–phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although missense mutations can occur throughout the molecule, they most frequently occur in the DBD.142,143”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [143]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ClinVar: improving access to variant interpretations and supporting evidence
Landrum, M. J., Lee, J. M., Benson, M., Brown, G. R., Chao, C., Chitipiralla, S., Gu, B., Hart, J., Hoffman, D., Jang, W., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1153 · Cited by 4,196
Mirabello, L., Troisi, R. J., & Savage, S. A. (2009) · Cancer · doi:10.1002/cncr.24121 · Cited by 2,199
Self-citationRevisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers
Bougeard, G., Renaux-Petel, M., Flaman, J.-M., Charbonnier, C., Fermey, P., Belotti, M., Gauthier-Villars, M., Stoppa-Lyonnet, D., Consolino, E., Brugières, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5728 · Cited by 760
Mutational processes shape the landscape of TP53 mutations in human cancer
Giacomelli, A. O., Yang, X., Lintner, R. E., McFarland, J. M., Duby, M., Kim, J., Howard, T. P., Takeda, D. Y., Ly, S. H., Kim, E., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0204-y · Cited by 556
Villani, A., Shore, A., Wasserman, J. D., Stephens, D., Kim, R. H., Druker, H., Gallinger, B., Naumer, A., Kohlmann, W., Novokmet, A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30249-2 · Cited by 546
Research works printed but not linked: 26
- Guha, 2017, Inherited TP53 mutations and the Li-Fraumeni syndrome, Cold Spring Harb Perspect Med, 7, 10.1101/cshperspect.a026187 · DOI · Paper page
- Mai, 2016, Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort, Cancer, 122, 3673, 10.1002/cncr.30248 · DOI · Paper page
- Kratz, 2017, Cancer screening recommendations for individuals with Li-Fraumeni syndrome, Clin Cancer Res, 23, e38, 10.1158/1078-0432.CCR-17-0408 · DOI · Paper page
- Ross, 2017, The psychosocial effects of the Li-Fraumeni education and early detection (LEAD) program on individuals with Li-Fraumeni syndrome, Genet Med, 19, 1064, 10.1038/gim.2017.8 · DOI
- Young, 2019, Couples coping with screening burden and diagnostic uncertainty in Li-Fraumeni syndrome: connection versus independence, J Psychosoc Oncol, 37, 178, 10.1080/07347332.2018.1543376 · DOI
- Fortuno, 2020, Genotype-phenotype correlations among TP53 carriers: literature review and analysis of probands undergoing multi-gene panel testing and single-gene testing, Cancer Genet, 248–249, 11, 10.1016/j.cancergen.2020.09.002 · DOI
- Gargallo, 2020, Li-Fraumeni syndrome heterogeneity, Clin Transl Oncol, 22, 978, 10.1007/s12094-019-02236-2 · DOI
- Rana, 2018, Differences in TP53 mutation carrier phenotypes emerge from panel-based testing, J Natl Cancer Inst, 110, 863, 10.1093/jnci/djy001 · DOI
- Frebourg, 2020, Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes, Eur J Hum Genet, 28, 1379, 10.1038/s41431-020-0638-4 · DOI · Paper page
- Rana, 2019, Genotype-phenotype associations among panel-based TP53+ subjects, Genet Med, 21, 2478, 10.1038/s41436-019-0541-y · DOI
- Fortuno, 2021, Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants, Hum Mutat, 42, 223, 10.1002/humu.24152 · DOI · Paper page
- Bouaoun, 2016, TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data, Hum Mutat, 37, 865, 10.1002/humu.23035 · DOI · Paper page
- Kaplan, 1958, Nonparametric-estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452 · DOI · Paper page
- Gaynor, 1993, On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data, J Am Stat Assoc, 88, 400, 10.1080/01621459.1993.10476289 · DOI · Paper page
- Aalen, 1978, An empirical transition matrix for non-homogeneous Markov chains based on censored observations, Scand J Stat, 5, 141
- Li, 1988, A cancer family syndrome in twenty-four kindreds, Cancer Res, 48, 5358
- Chompret, 2001, Sensitivity and predictive value of criteria for p53 germline mutation screening, J Med Genet, 38, 43, 10.1136/jmg.38.1.43 · DOI · Paper page
- Tinat, 2009, 2009 version of the Chompret criteria for Li Fraumeni syndrome, J Clin Oncol, 27, e108, 10.1200/JCO.2009.22.7967 · DOI · Paper page
- Eeles, 1995, Germline mutations in the TP53 gene, Cancer Surv, 25, 101
- Birch, 1994, Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families, Cancer Res, 54, 1298
- Ognjanovic, 2012, Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database, Cancer, 118, 1387, 10.1002/cncr.26390 · DOI · Paper page
- Amadou, 2018, Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome, Curr Opin Oncol, 30, 23, 10.1097/CCO.0000000000000423 · DOI · Paper page
- Ferrari, 2011, Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database, Pediatr Blood Cancer, 57, 943, 10.1002/pbc.23252 · DOI · Paper page
- Noone, 2017, cancer incidence and survival trends by subtype using data from the Surveillance Epidemiology and End Results Program, 1992–2013, Cancer Epidemiol Biomarkers Prev, 26, 632, 10.1158/1055-9965.EPI-16-0520 · DOI · Paper page
- Olivier, 2003, Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype, Cancer Res, 63, 6643
- Gonzalez, 2009, Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations, J Clin Oncol, 27, 1250, 10.1200/JCO.2008.16.6959 · DOI · Paper page
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- de Andrade, K. C., Khincha, P. P., Hatton, J. N., Frone, M. N., Wegman-Ostrosky, T., Mai, P. L., Best, A. F., & Savage, S. A.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2021-12
- Volume
- 22
- Issue
- 12
- Pages
- 1787-1798
- ISSN
- 1470-2045
- Cited by
- 135
- References
- 5
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- National Cancer Institute Division of Cancer Epidemiology and Genetics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancer incidence, patterns, and genotype–phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. https://app.cochat.ai/papers/10.1016/s1470-2045(21)00580-5
- The paper
- de Andrade, K. C., Khincha, P. P., Hatton, J. N., Frone, M. N., Wegman-Ostrosky, T., Mai, P. L., Best, A. F., & Savage, S. A. (2021). Cancer incidence, patterns, and genotype–phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(21)00580-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
